Amanda Cass

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

2h-index14citations14works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(10), Lung Cancer Diagnosis and Treatment(7), Lung Cancer Research Studies(6), Radiomics and Machine Learning in Medical Imaging(3), Radiopharmaceutical Chemistry and Applications(2)

Publications14 total

Safety and preliminary efficacy results of [ <sup>212</sup> Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).
Journal of Clinical Oncology·2026
Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
Cancer Treatment and Research Communications·2025Open Access
Outcomes of Concurrent Radiotherapy with Tarlatamab in Extensive-Stage Small Cell Lung Cancer from the DLL3 PanTUMOR Database
SSRN Electronic Journal·2025Open Access
Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer
Pharmacoepidemiology and Drug Safety·2024· 1 citedOpen Access
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated Non-Small Cell Lung Cancer: An ATOMIC Registry Analysis
UNC Libraries·2024Open Access
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
JTO Clinical and Research Reports·2024· 1 citedOpen Access
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
JTO Clinical and Research Reports·2024· 3 citedOpen Access
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer
2024Open Access
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
JTO Clinical and Research Reports·2024· 8 citedOpen Access
Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
SSRN Electronic Journal·2024Open Access
Opioid Tapering in Cancer Pain: A Prospective Study
Journal of Pain & Palliative Care Pharmacotherapy·2023
Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).
Journal of Clinical Oncology·2023· 1 cited
CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
Journal of the National Comprehensive Cancer Network·2023
Characterization of avoidable hospital admissions in patients with lung cancer in the immunotherapy and targeted therapy era.
Journal of Clinical Oncology·2022

Frequent Co-authors

Wade T. Iams(8), Tejas Patil(7), Melina E. Marmarelis(7), D. Ross Camidge(7), Connor B. Grady(6), Wei‐Ting Hwang(6), Fangdi Sun(6), Geoffrey Liu(6), Devalben Patel(6), Jorge J. Nieva(6), Kristen A. Marrone(6), Stephen V. Liu(6), Jared Weiss(6), William Schwartzman(6), Liza C. Villaruz(6), Charu Aggarwal(6), Lova Sun(6), Dara L. Aisner(5), Amanda Herrmann(5), Vincent K. Lam(5)